Killing of non-Hodgkin lymphoma cells by autologous CD19 engineered T cells.
AffiliationCancer Research UK Department of Medical Oncology, University of Manchester and Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Manchester M20 4BX, UK.
MetadataShow full item record
AbstractAdoptive immunotherapy with tumour-specific T cells is an emerging technology that may be applicable to a broad range of cancers. However, tumours can avoid T cell-mediated attack through multiple mechanisms including downregulation of major histocompatability complex (MHC). Consequently, engineering T cells to target intact protein antigen directly, thus bypassing the need for MHC presentation, can facilitate T cell targeting of tumour cells. Peripheral blood lymphocytes from nine of nine patients with non-Hodgkin lymphoma (NHL) were successfully gene-modified to express a receptor consisting of a CD19 single chain variable fragment (scFv) fused to the T cell CD3zeta signalling molecule. These T cells were functionally active against the CD19(+) Raji Burkitt's lymphoma cell line. Importantly, engineered T cells from seven of nine NHL patients efficiently lysed autologous lymph node tumour biopsy cells. There was a clear correlation between levels of CD19 expression on the tumour and effective killing by the engineered T cells. For two patients with a low or absent CD19(+) cells within the biopsy, no significant killing was observed. These results demonstrate that patients with CD19(+) NHL would be suitable candidates for this form of therapy in the setting of a phase I clinical trial.
CitationKilling of non-Hodgkin lymphoma cells by autologous CD19 engineered T cells. 2005, 129 (3):322-32 Br. J. Haematol.
JournalBritish Journal of Haematology
- A superantigen-antibody fusion protein for T-cell immunotherapy of human B-lineage malignancies.
- Authors: Gidlöf C, Dohlsten M, Lando P, Kalland T, Sundström C, Tötterman TH
- Issue date: 1997 Mar 15
- Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma.
- Authors: Mihara K, Yanagihara K, Takigahira M, Kitanaka A, Imai C, Bhattacharyya J, Kubo T, Takei Y, Yasunaga S, Takihara Y, Kimura A
- Issue date: 2010 Oct
- Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma.
- Authors: Cooper LJ, Ausubel L, Gutierrez M, Stephan S, Shakeley R, Olivares S, Serrano LM, Burton L, Jensen MC, Forman SJ, DiGiusto DL
- Issue date: 2006
- Activated T-cell-mediated immunotherapy with a chimeric receptor against CD38 in B-cell non-Hodgkin lymphoma.
- Authors: Mihara K, Yanagihara K, Takigahira M, Imai C, Kitanaka A, Takihara Y, Kimura A
- Issue date: 2009 Sep
- Human gammadelta T cells as mediators of chimaeric-receptor redirected anti-tumour immunity.
- Authors: Rischer M, Pscherer S, Duwe S, Vormoor J, Jürgens H, Rossig C
- Issue date: 2004 Aug